<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00636220</url>
  </required_header>
  <id_info>
    <org_study_id>P-HIV-01</org_study_id>
    <secondary_id>UMB Protocol # H-29110</secondary_id>
    <nct_id>NCT00636220</nct_id>
  </id_info>
  <brief_title>Evaluation of the DPP HIV 1/2 Test and the HIV 1/2 Stat Pak Test Using Oral Fluid</brief_title>
  <acronym>HIVOF</acronym>
  <official_title>Evaluation of the DPP HIV Test With Reader and the HIV 1/2 Stat-Pak Test Using Oral Fluids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chembio Diagnostic Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chembio Diagnostic Systems, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is intended to test the feasibility of using the HIV 1/2 STAT-PAK and the DPP
      HIV 1/2 test (with and without the DPP Handheld Reader) to detect HIV antibodies in oral
      fluids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate the feasibility of using fresh oral fluid
      specimens, from known HIV-positive individuals, to test for HIV-1 antibodies using both the
      DPP HIV 1/2 and HIV 1/2 STAT-PAK tests. Two oral fluid collection devices will be used and
      compared (MPC and Chembio collection devices) and the results obtained from oral fluids will
      be compared with those obtained from whole blood and plasma using paired samples from the
      same participants. The comparison between oral fluid, whole blood and plasma will be made in
      both Chembio devices (HIV 1/2 STAT-PAK and DPP HIV 1/2).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Fresh Oral Fluid Samples With Known HIV (+) Status and HIV Reactivity</measure>
    <time_frame>1 to 3 days</time_frame>
    <description>Known HIV status determined clinically or serologically. HIV reactivity for all 100 samples determined first by licensed EIA and then confirmed with Western Blot and/or NAT testing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Effectiveness of MPC and Chembio Oral Fluid Collection Devices</measure>
    <time_frame>1-3</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">101</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>A, Observational</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      oral fluid samples and venous blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of 100 participants with known (clinically or serologically)
        confirmed HIV infection. The participants, recruited by the staff of the Laboratory of Vial
        Diagnostics from the Evelyn Jordan Center, may be males or females (including pregnant
        women) at least 12 years of age from any ethnic and racial background.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with known HIV infection who are willing to participate in the study and
             who sign an informed consent (or assent), will be included in the study.

          -  Patients on HAART treatment for HIV will be included, but this information as well as
             the dates (duration) of treatment will be obtained through the interview of study
             participants; a medical record review is not necessary or required. The study
             participant's responses will be recorded by study staff on a Data Collection Form.

          -  Patients with immunosuppressive conditions other than HIV will be included if
             available, but will be limited to &lt; 25% of the total test population.
             Immunosuppression will also be assessed through interview of study participants and/or
             through verbal confirmation by the treating physician; a medical record/chart review
             is not required.

          -  Patients must be willing to undergo venipuncture to donate one tube of EDTA whole
             blood (not more than 10cc), and to provide three oral fluid samples.

        Exclusion Criteria:

          -  Patients who do not consent, withdraw consent, or for whom the investigator determines
             that venipuncture or gum swabbing may create a health risk will be excluded from the
             study.

          -  Participants who have been enrolled in HIV vaccine studies will be excluded from the
             study. This will be ascertained through interview of study participants.

          -  Participants who have been enrolled once in this study will be excluded from repeat
             enrollment.

          -  Participants must not have introduced any substance into their oral cavity (gum, food,
             beverage, candy, lozenges, mouthwash, etc.) for 30 minutes prior to providing an oral
             fluid sample. This will be ascertained through interview of study participants.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niel Constantine, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Evelyn Jordan Center, University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2008</study_first_submitted>
  <study_first_submitted_qc>March 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2008</study_first_posted>
  <results_first_submitted>January 8, 2009</results_first_submitted>
  <results_first_submitted_qc>January 20, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 15, 2010</results_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1 Infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment time period was from March 13, 2008 to July 1, 2008. All enrollment was at the Evelyn Jordan Center, University of Maryland Baltimore (UMD).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Confirmed HIV Infection</title>
          <description>The study population will consist of 100 participants with known (clinically or serologically) confirmed HIV infection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Confirmed HIV Infection</title>
          <description>participants with known (clinically or serologically) confirmed HIV infection.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fresh Oral Fluid Samples with known HIV reactivity</title>
          <description>Fresh Oral Fluid samples were collected from participants with known HIV+ status. HIV reactivity was clinically or serologically confirmed.</description>
          <units>samples</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants with known HIV reactivity</title>
          <description>participants with known HIV reactivity</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Fresh Oral Fluid Samples With Known HIV (+) Status and HIV Reactivity</title>
        <description>Known HIV status determined clinically or serologically. HIV reactivity for all 100 samples determined first by licensed EIA and then confirmed with Western Blot and/or NAT testing.</description>
        <time_frame>1 to 3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Confirmed HIV Infection</title>
            <description>The study population will consist of 100 participants with known (clinically or serologically) confirmed HIV infection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Fresh Oral Fluid Samples With Known HIV (+) Status and HIV Reactivity</title>
          <description>Known HIV status determined clinically or serologically. HIV reactivity for all 100 samples determined first by licensed EIA and then confirmed with Western Blot and/or NAT testing.</description>
          <units>samples</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effectiveness of MPC and Chembio Oral Fluid Collection Devices</title>
        <time_frame>1-3</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Confirmed HIV Infection</title>
          <description>The study population will consist of 100 participants with known (clinically or serologically) confirmed HIV infection.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Javan Esfandiari</name_or_title>
      <organization>Chembio Diagnostic Systems, Inc.</organization>
      <phone>(631) 924-1135 ext 112</phone>
      <email>jesfandiari@chembio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

